APRIL and BAFF play a key role in differentiating vitreoretinal lymphoma from uveitis

Clin Chim Acta. 2022 Oct 1:535:1-6. doi: 10.1016/j.cca.2022.06.014. Epub 2022 Jul 9.

Abstract

Background: Early diagnosis of vitreoretinal lymphoma (VRL) is critical for the successful treatment of this rare intraocular malignancy. However, fast and reliable diagnosis of VRL in patients presenting with intermediate or posterior non-infectious uveitis remains a challenge. A proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF) are vital factors in the pathophysiology, diagnosis, and prognosis of primary central nervous system lymphoma (PCNSL) and systemic autoimmune diseases. However, their utility as biomarkers for the diagnosis of VRL and uveitis remains unclear.

Methods: In this retrospective study, we analyzed APRIL and BAFF levels in the aqueous humor (AH) of 43 eyes of 40 patients, including 23 eyes of 20 patients with VRL, eight eyes of eight patients with uveitis, and 12 eyes of 12 patients with other ocular diseases (OODs). Additionally, we measured their levels after induction of chemotherapy in five eyes of five patients with VRL.

Results: AH levels of APRIL reliably distinguished VRL from uveitis, with a specificity of 78.3% and sensitivity of 75%. BAFF also showed similar potential. Serial AH analysis of patients with VRL during chemotherapy demonstrated a corresponding decline in AH levels of APRIL and BAFF.

Conclusion: This study extends the spectrum of valuable diagnostic biomarkers for VRL and uveitis. In patients with uveitis, the assessment of AH APRIL may help accelerate the diagnosis of VRL. Moreover, our results underline the important role of APRIL and BAFF in therapeutic monitoring of VRL.

Keywords: APRIL; Aqueous humor (AH); BAFF; Uveitis; Vitreoretinal lymphoma (VRL).

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Aqueous Humor / chemistry
  • B-Cell Activating Factor* / analysis
  • Biomarkers / analysis
  • Biomarkers, Tumor / analysis
  • Diagnosis, Differential
  • Humans
  • Lymphoma* / diagnosis
  • Lymphoma* / drug therapy
  • Lymphoma* / genetics
  • Retinal Neoplasms* / diagnosis
  • Retinal Neoplasms* / drug therapy
  • Retinal Neoplasms* / genetics
  • Retrospective Studies
  • Tumor Necrosis Factor Ligand Superfamily Member 13* / analysis
  • Uveitis* / diagnosis
  • Uveitis* / genetics
  • Vitreous Body*

Substances

  • Antineoplastic Agents
  • B-Cell Activating Factor
  • Biomarkers
  • Biomarkers, Tumor
  • TNFSF13 protein, human
  • Tumor Necrosis Factor Ligand Superfamily Member 13